$0.21
+0.00 (+0.14%)
USD · as of 2026-08-19 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BRTX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
1 interventional
Held by 3 tracked-famous managers (JANE STREET GROUP, LLC, CITADEL ADVISORS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 1.1 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)NCT04042844Primary Safety MeasuresRandomized · Double-masked · Treatment | Phase 2 | Recruiting | Biological: BRTX-100 · Drug: Saline | Lumbar Disc Disease | 99 | Dec 2026 | ≤ 133 d | 2025-08-26 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19